Sarepta Therapeutics’ (SRPT) Underperform Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their underperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Thursday,Benzinga reports.

Other research analysts have also issued reports about the company. Wedbush cut their target price on Sarepta Therapeutics from $34.00 to $29.00 and set an “outperform” rating for the company in a research note on Monday, March 2nd. Wells Fargo & Company lowered their price target on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Royal Bank Of Canada increased their price objective on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a research note on Thursday, January 8th. Loop Capital set a $25.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Finally, Barclays started coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 target price on the stock. Nine analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Hold” and an average target price of $32.30.

Sarepta Therapeutics Trading Down 8.8%

Shares of SRPT opened at $21.68 on Thursday. Sarepta Therapeutics has a 12-month low of $10.41 and a 12-month high of $73.95. The company has a quick ratio of 1.48, a current ratio of 2.32 and a debt-to-equity ratio of 0.73. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of -2.57, a P/E/G ratio of 0.37 and a beta of 0.42. The stock’s 50-day moving average price is $18.71 and its 200 day moving average price is $19.97.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The firm had revenue of $442.93 million during the quarter, compared to analyst estimates of $390.95 million. During the same period last year, the company earned $1.90 EPS. The company’s revenue was down 32.7% on a year-over-year basis. As a group, research analysts predict that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total transaction of $123,207.78. Following the completion of the transaction, the director directly owned 1,765 shares in the company, valued at $30,040.30. This represents a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rockefeller Capital Management L.P. grew its holdings in shares of Sarepta Therapeutics by 98.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 4,104 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 2,034 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in Sarepta Therapeutics by 340.7% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 95,752 shares of the biotechnology company’s stock valued at $2,061,000 after purchasing an additional 74,027 shares during the last quarter. EP Wealth Advisors LLC bought a new position in Sarepta Therapeutics during the 4th quarter valued at about $213,000. Mackenzie Financial Corp boosted its position in Sarepta Therapeutics by 17.1% in the fourth quarter. Mackenzie Financial Corp now owns 58,042 shares of the biotechnology company’s stock valued at $1,245,000 after buying an additional 8,494 shares in the last quarter. Finally, Virtus Investment Advisers LLC boosted its position in Sarepta Therapeutics by 166.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 31,741 shares of the biotechnology company’s stock valued at $683,000 after buying an additional 19,830 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Key Headlines Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Early Phase 1/2 siRNA results point to target knockdown, muscle exposure and tolerability for SRP‑1001 and SRP‑1003 — the primary catalyst behind the rally. Business Wire: Sarepta Announces First Clinical Data
• Positive Sentiment: Multiple outlets and market commentators highlight the clinical readouts as a potential turning point; coverage helped drive heavy volume and momentum into the stock. Yahoo Finance: SRPT Stock Surges
• Positive Sentiment: Some sell‑side moves reflected renewed conviction — Morgan Stanley is reported to have raised its price target (reported widely alongside the trial coverage), which helped fuel the rally. InsiderMonkey: Morgan Stanley PT Hike
• Positive Sentiment: Unusually heavy options and call buying accompanied the move, indicating speculative bullish positioning and short‑term leverage from traders.
• Neutral Sentiment: Several valuation and note‑style writeups are trying to size the opportunity vs. risk — analysts and outlets caution that early Phase 1/2 data need confirmation and that valuation debate will drive near‑term swings. Yahoo/Zacks coverage: Is Further Upside Left?
• Negative Sentiment: Some firms remain skeptical — Citigroup raised a price target modestly but kept a sell rating (cites downside from current levels), and Needham reaffirmed an underperform stance, keeping sell‑side views polarized. Benzinga: Analyst Ratings
• Negative Sentiment: Independent analysts and commentators warn the data are early — some outlets argue it’s too soon to extrapolate durable clinical or commercial success from small Phase 1/2 cohorts. Seeking Alpha: Too Early to Get Excited
• Negative Sentiment: Underlying fundamentals and priorquarter results (recent EPS miss and revenue decline vs. year‑ago) remain a drag on sentiment; this increases the chance of volatility if follow‑up data or guidance disappoints.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.